GLP1R and obesity due to melanocortin 4 receptor deficiency: The American Association of Clinical Endocrinology and the American Diabetes Association recommend GLP-1 RAs for patients with T2DM who have chronic kidney disease, atherosclerotic cardiovascular disease risk, or obesity [6, 7].